Chronic inflammation of the prostate type IV with respect to risk of prostate cancer


Submitted: October 10, 2014
Accepted: October 10, 2014
Published: September 30, 2014
Abstract Views: 2498
PDF: 1010
SUPPLEMENTARY MATERIAL: 347
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Antonio B. Porcaro Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Emanuele Rubilotta Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Aldo Petrozziello Geriatric Medicine/Endocrinology, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Claudio Ghimenton Pathology, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Filippo Migliorini Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Stefano Zecchini Antoniolli Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Vincenzo Lacola Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Carmelo Monaco Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Pierpaolo Curti Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Stefano Cavalleri Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Romeo Pianon Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Walter Artibani Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Background: Chronic inflammatory infiltrate (CII) might be involved in prostate cancer (PCA) and benign hyperplasia (BPH); however, its significance is controversial. Chronic inflammatory prostatitis type IV is the most common non cancer diagnosis in men undergoing biopsy because of suspected PCA. Objective: To evaluate potential associations of coexistent CII and PCA in biopsy specimens after prostate assessment. Design, setting, and participants: Between January 2007 and December 2008, 415 consecutive patients who underwent prostate biopsy were retrospectively evaluated. The investigated variables included Age (years) and PSA (ug/l); moreover, CII+, glandular atrophy (GA+), glandular hyperplasia (GH+), prostate Intraepithelial neoplasm (PIN+), atypical small acinar cell proliferation (ASAP+) and PCA positive cores (P+) were evaluated as categorical and continuous (proportion of positive cores). Outcome measurements and statistical analysis: Associations of CII+ and PCA risk were assessed by statistical methods. Results and limitations: In the patient population, a biopsy core positive for PCA was detected in 34.2% of cases and the rate of high grade PCA (HGPCA: bGS ! 8) resulted 4.82%. CII+ significantly and inversely associated with a positive biopsy core P+ (P < 0.0001; OR = 0.26) and HGPCA (P = 0.0005; OR = 0.05). Moreover, the associations indicated that patients with coexistent CII+ on needle biopsy were 74% less likely to have coexistent PCA than men without CII+ as well as 95% less likely to have HGPCA in the biopsy core than men without coexistent CII+. There were limits in our study which was single centre and included only one dedicated pathologist. Conclusions: There was an inverse association of chronic inflammation of the prostate type IV and risk of PCA; moreover, HGPCA was less likely to be detected in cancers associated with coexistent CII. In prostate microenvironment, prostate chronic inflammation may be protective; however, its role in PCA carcinogenesis remains controversial and needs further research.

Porcaro, A. B., Rubilotta, E., Petrozziello, A., Ghimenton, C., Migliorini, F., Zecchini Antoniolli, S., Lacola, V., Monaco, C., Curti, P., Cavalleri, S., Pianon, R., & Artibani, W. (2014). Chronic inflammation of the prostate type IV with respect to risk of prostate cancer. Archivio Italiano Di Urologia E Andrologia, 86(3), 208–211. https://doi.org/10.4081/aiua.2014.3.208

Downloads

Download data is not yet available.

Citations


Similar Articles

You may also start an advanced similarity search for this article.